OUr Sponsors and Partners

The Helmsley Charitable Trust

The goal of the Helmsley Charitable Trust T1D Program is to improve the lives of all people living with type 1 diabetes (T1D). Working closely with key players across the T1D ecosystem – patients, physicians, caregivers, researchers, government agencies, funders, pharmaceutical companies, device makers, insurers, and community organizations – the Helmsley Charitable Trust seek to improve care and ultimately prevent the disease. 


JDRF is leading the fight against type 1 diabetes (T1D) by funding research, advocating for policies that accelerate access to new therapies, and providing a support network for millions of people around the world impacted by T1D. Outside of the lab, JDRF pushes for increased government funding for research, and work with academia, clinicians, insurers, and regulators to get new therapies and devices to market quickly and safely.


HuBMAP Highlights

The goal of the Human BioMolecular Atlas Program (HuBMAP) is to develop an open and global platform to map healthy cells in the human body.  HuBMAP researchers are studying the connections that cells have with each other throughout the body to determine how the relationships between cells can affect the health of an individual.


The NIDDK’s mission is to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases, to improve people’s health and quality of life.



TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. TrialNet offers risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression by preserving insulin production before and after diagnosis. 

The Environmental Determinants of Diabetes in the Young (TEDDY) study will investigate:

  • genetic and genetic-environmental interactions, including gestational infection or other gestational events
  • childhood infections or other environmental factors after birth in relation to the development of prediabetic autoimmunity and Type I Diabetes Mellitus (T1DM). The consortium of six centers has been assembled to participate in the development and implementation of studies to identify environmental factors that trigger the development of T1DM in genetically susceptible individuals.